Reversible bradycardia secondary to myxedema coma: case-report

Omar Kousa¹, Mohamed Mansour², Dana Awad¹,*, Amr Essa¹, Abdallah Qasim¹, Arindam Sharma³ and Mark Holmberg³

¹Creighton University School of Medicine, Department of Internal Medicine 7500 Mercy Road, Omaha, NE 68124, USA  
²Sheikh Shakhbout Medical City, Department of Internal Medicine, Abu-Dhabi, UAE  
³Division of Cardiology, Department of Medicine, Creighton University School of Medicine, Omaha, NE 68124, USA

*Correspondence: Danaawad@creighton.edu (Dana Awad)

DOI: 10.31083/j.rcm.2020.02.26

This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0/).

Myxedema coma occurs mostly in patients with long-standing untreated or undertreated hypothyroidism. Bradycardia is a well-known cardiac manifestation for myxedema coma; however, not all bradycardia with hypothyroidism are sinus bradycardia. Sick sinus syndrome is a group of arrhythmias caused by the malfunction of the natural pacemaker of the heart. Tachy-Brady syndrome is considered to be a type of sick sinus syndrome, where the heart alternates between tachycardia and bradycardia, and it is usually treated with pacemaker implantation along with rate slowing medical therapy. Here we report a case of an 83-year-old female who presented with myxedema coma and atrial fibrillation with tachycardia and intermittent slow ventricular response. We attempt to review the relationship between these two diseases and conclude that appropriate diagnosis of myxedema coma, may be beneficial in reducing the need for pacemaker implantation.

Keywords
Atrial fibrillation with slow ventricular rate; hypothyroidism; myxedema; case report

1. Introduction
Bradycardia is defined as heart rate of less than 60 beats per minute. It can be caused by intrinsic or extrinsic abnormalities. Intrinsic causes, such as age-related degeneration or infarction of sinus nodal tissues, whereas extrinsic causes include negative chronotropic pharmacologic agents, electrolyte imbalances, hypothermia, as well as hypothyroidism (Mangrum and DiMarco, 2000). Approximately one million pacemaker implantation occur worldwide secondary to bradycardia (Mond and Proclemer, 2011; Raatikainen et al., 2015). Myxedema coma is typically a sequelae of chronic thyroid hormone deficiency and is characterized by the deterioration of mental status, hypothermia, hypotension, hypoponatemia, and hypoventilation. It is considered to be an endocrine emergency. In the past, the overall mortality rate for myxedema coma was 60%-70%. Early disease recognition and advancements in the care provided to these patients have reduced the mortality rate to 20%-50% (Ueda et al., 2019). A precipitating event on a background history of long-standing, untreated, or inadequately treated hypothyroidism may result in myxedema coma. Infections, drugs such as: narcotics, anesthetics, and sedatives, in addition to lung diseases, congestive heart failure, and gastrointestinal bleeding maybe some of the precipitating events (Dhakal et al., 2015). In this review, we aim to emphasize the importance of recognition of the underlying cause of bradyarrhythmia before proceeding with pacemaker implantation in the setting of myxedema coma.

2. Case presentation
An 83-year-old female was brought to the emergency department after she was noted to have a low oxygen saturation at home. She was recently admitted due to acute kidney injury, and her diuresis was held on discharge. On further questioning, she reported having a non-productive cough and mild shortness of breath for the last few days. She reported no new sick contact or travel history. She has a past medical history of hypertension treated with amlodipine, permanent atrial fibrillation on rivaroxaban for CHADSVASc score of 5, hypothyroidism treated with levothyroxine, lower limb edema on furosemide as needed and hyperepiglotticemia treated with atorvastatin. It was noted that she had inadequate medication compliance for the last five months. Social history was negative for smoking, alcohol use, or illicit drug use. Family history was significant for diabetes mellitus. She had no known allergies. A review of systems was positive for cold intolerance, puffiness around the eyes, constipation, and sluggish responses. On arrival to the emergency department, she was noted to be hypoxic, requiring 2 liters of oxygen via nasal cannula to maintain oxygen saturation above 90%. Blood pressure and heart rates were 145/61 mmHg and 62 beats per minute, respectively. She was mildly confused to time and place, had an irregular pulse, jugular venous distention, positive hepatojugular reflux, bilateral inspiratory wheezes on lung auscultation, bilateral pitting edema up to the mid-shin, and slow deep tendon reflexes were noted. The rest of the examination was unremarkable. Initial laboratory workup revealed elevated brain natriuretic peptide (Table 1). Electrocardiogram showed atrial fibrillation with a heart rate of 60 beats per minute (Fig. 1). Chest radiograph (CXR) showed mild pulmonary edema (Fig. 2). She was admitted as acute hypoxic res-
piratory failure secondary to pulmonary edema due to heart failure exacerbation and was subsequently started on intravenous diuretics. Overnight, her heart rate dropped to 13 beats per minute (Fig. 3). Electrocardiogram before admission showed atrial fibrillation with a mildly rapid ventricular rate (Fig. 4), and occasional tachycardia was also noted on telemetry. Cardiac monitor overnight showed evidence of recurrent bradycardia (Fig. 5A,B).

Cardiology was consulted for pacemaker implantation in the setting of bradycardia. Echocardiography showed an ejection fraction of 55%, eccentric left ventricular hypertrophy, mild reduced right ventricular systolic function, and right ventricular systolic pressure of 52.9 mmHg. There was trace anterior pericardial effusion noted on the echocardiogram. Thyroid-stimulating hormone was ordered, and it came back significantly elevated at 96.7 UIU/L (Table 1). On further assessment by cardiology service, it was determined that she had congestive heart failure associated with bradycardia, which was attributed to hypothyroidism, and hormone replacement was recommended with no recommendation for pacemaker insertion at that time. On follow-up, the patient was subsequently started on levothyroxine 200 mcg for a minimum of 2 weeks, with a plan to recheck her thyroid-stimulating hormone and free thyroxine level in 2-3 weeks and titrate down to 150 mcg accordingly.

A few days later, her symptoms resolved, with the resolution of bradycardia documented by continuous cardiac monitoring. Interestingly, no significant tachycardia was seen following initiation of thyroxine with maximum heart rates around 101-105 bpm with highest rate on day 2 of levothyroxine of 121 bpm. A week later, her thyroid-stimulating hormone level was down to 15.3 UIU/L, and repeat CXR showed resolved pulmonary edema (Fig. 6). She was discharged in a stable condition on a tapering dose of levothyroxine, with close follow-up with her primary care physician and endocrinology.

3. Discussion

Untreated hypothyroidism is known to affect almost all organs, including the cardiovascular system. It is associated with a decrease in cardiac output, stroke volume due to decreased myocardial contractility, and an increase in systemic vascular resistance.
It can cause cardiac arrhythmias, the most commonly seen conduction abnormalities being sinus bradyarrhythmia, heart block, ventricular tachycardia, and torsade de points. In addition, diastolic hypertension has been observed in the early stages due to peripheral vasoconstriction and central shunting of blood. Pericardial effusions may also be present in such cases due to increased vascular permeability (Salhan et al., 2017). Supraventricular arrhythmias, including atrial fibrillation, can be seen in around 50% of patients with sick sinus syndrome or sinus node dysfunction. In our patient atrial fibrillation with slow ventricular response was present. Correction of any possible underlying reversible cause for bradyarrhythmia should be sought first before consideration of pacemaker implantation.

To date, only a few studies have described patients with myxedema coma presenting with bradyarrhythmia’s, who were successfully treated with thyroid hormone replacement only, without the need for permanent pacemaker implantation. Harada et al. reported a case of a myxedema coma in an elderly male patient who presented with sick sinus syndrome and type two respiratory failure, which was successfully managed with thyroid hormone replacement (Harada et al., 2019). Also, Waseem et al. (2018) reported a case of an elderly male with a history of undertreated hypothyroidism who presented with atrial fibrillation with a slow ventricular response as well as a high degree atrioventricular block. The atrioventricular block resolved upon increasing the dose of levothyroxine, thus avoiding the need for permanent pacemaker implantation (Lee et al., 1986). Also, Schoenmakers et al. described a case of an elderly female who presented with a complete heart block and was found to be in myxedema coma. She was treated with low dose levothyroxine and required temporary pacing. After several days atrioventricular conduction was restored, and she did not require permanent pacemaker implantation (Schoenmakers et al., 2008). Furthermore, in a study of atrioventricular block in patients with thyroid dysfunction, conducted by Ozcan et al., 24% of patients with hypothyroidism and atrioventricular block had complete resolution of the atrioventricular block.
Figure 5. Two cardiac rhythm strips recorded during the patient’s stay in the intensive care unit, done 2-hours apart, showing atrial fibrillation with a slow ventricular response. Figure 5A shows a pause of around 3.2 sec. Figure 5B shows a pause of around 3.2 sec.

Figure 6. Chest radiograph was done one-week after initiation of thyroid replacement therapy and diuretics, showing resolution of the previously noted pulmonary congestion and the left-sided pleural effusion.

after treatment with thyroid hormone replacement (Ozcan et al., 2012). Older studies have also described an atrioventricular block in patients with myxedema, that resolved with thyroid hormone supplementation, without the need for cardiac pacing (Schantz and Dubbs, 1951; Singh et al., 1973).

4. Conclusion
Our case demonstrates the importance of recognizing severe hypothyroidism, and particularly myxedema coma, as a cause of bradyarrhythmia, especially in elderly patients presenting with nonspecific symptoms such as fatigue, presyncope, syncope or palpitations. Mortality rates associated with myxedema coma with cardiac complications is high. So, appropriate treatment of these patients with thyroid hormone replacement can spare them the need for permanent pacemaker placement, as well as reduce procedure-related risks and complications.

Authors’ contributions
• Omar Kousa, Mohamed Mansour, Dana Awad, Amr Essa and Abdallah Qasim had substantial contributions to the conception or design of the work, formulated the tables and figures, and drafting the work.
• Arindam Sharma and Mark Holmberg critically revised, edited the manuscript substantially and approved the final version of the current version.
• All authors agree and are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Table 1. Laboratory work up on presentation.

| Test                        | Result    | Reference Range |
|-----------------------------|-----------|-----------------|
| White Blood Cell            | 6.1 k/mL  | 4–12 k/mL       |
| Hemoglobin                  | 11 gm/dL  | 12–16 gm/dL     |
| Hematocrit                  | 33.20%    | 36–48 %         |
| Mean Corpuscular Volume     | 99 fl     | 80–100 fl       |
| Platelet                    | 288 k/mL  | 140–440 k/mL    |
| Glucose                     | 90 gm/dL  | 74–106 gm/dL    |
| Sodium                      | 140 mmol/L| 137–145 mmol/L  |
| Potassium                   | 3.1 mmol/L| 3.5–5.1 mmol/L  |
| Chloride                    | 105 mmol/L| 98–107 mmol/L   |
| Carbon Dioxide              | 30 mmol/L | 22–30 mmol/L    |
| Urea                        | 30 mg/dL  | 9–20 mg/dL      |
| Creatinine                  | 1.36 gm/dL| 0.7–1.2 gm/dL   |
| Total Protein               | 7 g/dL    | 6.3–8.2 g/dL    |
| Albumin                     | 4.1 g/dL  | 3.5–5.0 g/dL    |
| Calcium                     | 9.7 mg/dL | 8.4–10.2 mg/dL  |
| Total bilirubin             | 0.9 mg/dL | 0.2–1.3 mg/dL   |
| Aspartate Aminotransferase  | 70 IU/L   | 15–46 IU/L      |
| Alanine Transaminase        | 78 IU/L   | 4–50 IU/L       |
| Alkaline Phosphates         | 92 IU/L   | 38–126 IU/L     |
| Creatine Kinase             | 43 IU/L   | 55–170 IU/L     |
| Brain Natriuretic Peptide   | 4856 pg/ml| < 449 pg/ml     |
| Thyroid-stimulating hormone | 96.7 IU/L | 0.4–3.8 IU/L    |
| Troponin                    | < 0.04    | < 0.04          |
| Influenza antigen A & B     | negative  | negative        |
| Early morning cortisol      | 14.2 ug/dl| 5.3–22.4 ug/dl  |
| Thyroid peroxidase antibodies | 47 u/ml   | < 59 u/ml       |

Ethics approval and consent to participate
Our institution does not require ethical approval for reporting individual cases or case series. The consent was not obtained from the patient(s) due to unavailability. Any potential patient’s identifiers have been removed from the description/images and this paper has been anonymized not to cause any harm to the patient.

Acknowledgments
The authors declare no funding, no contribution from other persons.

Conflict of interest
The author declares no conflicts of interest.

References
Dhakal, P., Pant, M., Acharya, P. S., Dahal, S. and Bhatt, V. R. (2015) Myxedema coma with reversible cardiopulmonary failure: a rare entity in 21 century. *Maedica 10*, 268-271.
Harada, K., Murakami, S., Tokunasu, K., Togawa, Y. and Otsuka, F. (2019) Myxedema coma accompanied by sick sinus syndrome and hypventilation: A case report. *Journal of General and Family Medicine 20*, 206-208.
Lee, R. W., Huang, S. K., Mechling, E. and Bazган, I. (1986) Runaway atrioventricular sequential pacemaker after radiation therapy. *The American Journal of Medicine 81*, 883-886.
Mangrum, J. M. and DiMarco, J. P. (2000) The evaluation and management of bradycardia. *The New England Journal of Medicine 342*, 703-709.
Mond, H. G. and Proclemer, A. (2011) The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 -a World Society of Arrhythmia's project. *Pacing and Clinical Electrophysiology: PACE 34*, 1013-1027.
Ozcan, K. S., Osmonov, D., Erdinler, I., Altay, S., Yildirim, E., Turkkan, C., Hasdemir, H., Cakmak, N., Alper, A. T., Satilmis, S. and Gurkan, K. (2012) Atrioventricular block in patients with thyroid dysfunction: prognosis after treatment with hormone supplementation or antithyroid medication. *Journal of Cardiology 60*, 327-332.
Raataikainen, M. J. P., Arnar, D. O., Zeppenfeld, K., Merino, J. L., Levy, F., Hindriks, G. and Kuck, K.-H. (2015) Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. *Europe: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology 17 Suppl 1*, i1-75.
Salhan, D., Sapkota, D., Verma, P., Kandel, S., Abdulfattah, O., Lison, A., Zwenge, D. and Schmidt, F. (2017) Sudden cardiac arrest as a rare presentation of myxedema coma: case report. *Journal of Community Hospital Internal Medicine Perspectives 7*, 318-320.
Schantz, E. T. and Dubbs, A. W. (1951) Complete auriculoventricular block in myxedema with reversion to normal sinus rhythm on thyroid therapy. *American Heart Journal 41*, 613-619.
Schonenmakers, N., de Graaff, W. E. and Peters, R. H. J. (2008) Hypothyroidism as the cause of atrioventricular block in an elderly patient. *Netherlands Heart Journal: Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 16*, 57-59.
Singh, J. B., Starobin, O. E., Guerrant, R. L. and Manders, E. K. (1973) Reversible atrioventricular block in myxedema. *Chest 63*, 582-585.
Ueda, K., Kiyota, A., Tsuchida, M., Okazaki, M. and Ozaki, N. (2019) Successful treatment of myxedema coma with a combination of levotiroxine and liothyronine. *Endocrine Journal 66*, 469-474.
Waseem, H., Hashmi, A. T., Anser, M., Wali, N., Rodriguez, D. and Greenberg, Y. (2018) A pacemaker that was avoided. *Cureus 10*, e2555.